Reported about 7 hours ago
Allurion has launched a new program to provide compounded weight-loss drugs to patients as the FDA seeks to end access to these medications. CEO Shantanu Gaur explained that the decision is driven by the ongoing demand for GLP-1 drugs, despite the company's existing ingestible balloon solution. The program incorporates AI to support patients in maintaining their diet and exercise alongside the use of compounded semaglutide, with plans for tirzepatide to follow. Allurion, facing stock price challenges, sees this move as essential to re-engage with a market that has received increasing interest in recent times.
Source: YAHOO